Peter Maag - Caredx CEO and President and Director
| CDNA Stock | USD 24.91 0.21 0.84% |
CEO
Dr. Peter Maag, Ph.D. is Chief Executive Officer and Director of the Company. Dr. Maag has served as our Chief Executive Officer since October 2012 and as a member of our Board of Directors since November 2012. Dr. Maag also served as our President from October 2012 until November 2018. Prior to joining the Company, Dr. Maag held numerous positions with increasing responsibility at Novartis International AG, a global healthcare company from September 2001 to April 2012, including Global Head of Novartis Diagnostics, a business unit of Novartis A.G., from 2009 to 2012. Dr. Maag also served as Country President for Novartis Pharma AG in Germany from 2006 to 2008, Country President for Novartis Korea operations from 2003 to 2005, and the Head of Strategy for the pharmaceutical division of Novartis A.G. from 2001 to 2002. Dr. Maag also worked at McKinsey Company, focusing on healthcare and globalization from 1995 to 2001. Besides supporting various healthcare and tech companies in their growth efforts, Dr. Maag also holds a board position at Phoenix Pharma SE and serves on the board of Personalized Medicine Coalition in Washington D.C since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 8000 Marina Boulevard, South San Francisco, CA, United States, 94005 |
| Phone | 415 287 2300 |
| Web | https://caredx.com |
Latest Insider Transactions
Maag studied pharmaceutical sciences at the University of Heidelberg and University of London and received his Ph.D. from the University of Berlin, Germany.Peter Maag Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Maag against Caredx stock is an integral part of due diligence when investing in Caredx. Peter Maag insider activity provides valuable insight into whether Caredx is net buyers or sellers over its current business cycle. Note, Caredx insiders must abide by specific rules, including filing SEC forms every time they buy or sell Caredx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Maag over a month ago Disposition of 8844 shares by Peter Maag of Caredx at 33.23 subject to Rule 16b-3 | ||
Peter Maag over two months ago Disposition of 13890 shares by Peter Maag of Caredx at 33.25 subject to Rule 16b-3 | ||
Peter Maag over two months ago Disposition of 12818 shares by Peter Maag of Caredx at 32.67 subject to Rule 16b-3 | ||
Peter Maag over three months ago Disposition of 26708 shares by Peter Maag of Caredx at 7.96 subject to Rule 16b-3 |
Caredx Management Efficiency
The company has return on total asset (ROA) of (0.075) % which means that it has lost $0.075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4302) %, meaning that it created substantial loss on money invested by shareholders. Caredx's management efficiency ratios could be used to measure how well Caredx manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.52. In addition to that, Return On Capital Employed is expected to decline to -0.55. At present, Caredx's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 179.4 M, whereas Other Assets are projected to grow to (16.9 M).Similar Executives
| Found 11 records | CEO Age | ||
| Evguenia MBA | Sera Prognostics | 50 | |
| James JD | Charles River Laboratories | 73 | |
| Christopher Hall | Personalis | 55 | |
| Helmy Eltoukhy | Guardant Health | 45 | |
| Derek Maetzold | Castle Biosciences | 62 | |
| Paul JD | Myriad Genetics | 62 | |
| Scott Hutton | Biodesix | 52 | |
| Paul Diaz | Myriad Genetics | 62 | |
| Steven Chapman | Natera Inc | 45 | |
| Jacob Thaysen | Illumina | 49 | |
| Emily Leproust | Twist Bioscience Corp | 51 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.075 |
Caredx Inc Leadership Team
Elected by the shareholders, the Caredx's board of directors comprises two types of representatives: Caredx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caredx. The board's role is to monitor Caredx's management team and ensure that shareholders' interests are well served. Caredx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caredx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marco Scheller, Senior Operations | ||
| Ian Cooney, Vice Relations | ||
| Jessica Meng, Chief Officer | ||
| Jeffrey Novack, General Secretary | ||
| Hal Gibson, Senior Planning | ||
| GS Jha, Chief VP | ||
| Reginald Seeto, President Chief Business Officer | ||
| Sasha MBA, Ex Officer | ||
| Abhishek Jain, CFO Officer | ||
| Mickey MD, Sr Product | ||
| Peter Maag, CEO and President and Director | ||
| Abraham Esq, Chief Counsel | ||
| Kashif Rathore, Head Engineering | ||
| Stacey Follon, Senior Resources | ||
| Alexander Johnson, President Services | ||
| Jing Huang, Chief Officer | ||
| Marcel Konrad, Sr Accounting | ||
| CPA CFA, Chief Officer | ||
| Marica Grskovic, Chief Officer | ||
| Robert Woodward, Chief Officer | ||
| John Hanna, CEO President |
Caredx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caredx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.075 | ||||
| Profit Margin | (0.46) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 1.13 B | ||||
| Shares Outstanding | 53.63 M | ||||
| Shares Owned By Insiders | 3.43 % | ||||
| Shares Owned By Institutions | 96.00 % | ||||
| Number Of Shares Shorted | 3.07 M | ||||
| Price To Earning | (4.25) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Caredx Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Caredx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Caredx Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Caredx Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caredx Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Caredx. If investors know Caredx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Caredx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 5.952 | Quarterly Revenue Growth 0.234 | Return On Assets (0.07) | Return On Equity (0.43) |
The market value of Caredx Inc is measured differently than its book value, which is the value of Caredx that is recorded on the company's balance sheet. Investors also form their own opinion of Caredx's value that differs from its market value or its book value, called intrinsic value, which is Caredx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Caredx's market value can be influenced by many factors that don't directly affect Caredx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Caredx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Caredx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Caredx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.